['human immunodeficiency virus', 'hepatitis c, chronic']
['e/c/f/taf;', 'ledipasvir-sofosbuvir']

        Inclusion

          -  HIV infected (ELISA with western blot confirmation)

          -  HCV RNA positive for minimum of 6 months / Genotype 1

          -  Prescribed cART that may include any DHHS recommended or alternative regimens, which
             the treating physician considers, is appropriate for their patient. (We anticipate
             that approximately 60% will be on HIV protease inhibitor-based regimens).

          -  HIV RNA BLLQ for minimum of 3 months

          -  Stage 0 - 4 fibrosis

          -  No evidence of liver decompensation defined as past or current ascites, bleeding
             varices or hepatic encephalopathy. Prior interferon, ribavirin and/or HCV protease
             inhibitor exposure will be allowed with the exception of cirrhotic with a past history
             of null response to interferon-based therapy.

          -  Ability to remain adherent to medications and study protocol as per investigator
             opinion

          -  For female subjects, not pregnant, planning or suspected to be pregnant or
             breast-feeding

          -  Willing to use acceptable methods of birth control, as defined in protocol

          -  Active substance use and/or mental health issues will not be exclusionary assuming
             other criteria are met. This inclusion will be restricted to those stably housed and
             engaged in harm reduction strategies. Our intent is to evaluate study participants who
             are representative of our clinical population and consider 'difficult to cure'
             compared to populations already evaluated in licensing studies

        Exclusion:

          -  Concomitant use of drugs with contraindication drug interactions with E/C/F/TAF of
             SOF-LDV

          -  History of HIV integrase inihbitors or NRTI resistance mutations

          -  Platelets <50 x109/L
      